• Basic Membership Access to Journal, Shadow Stock portfolio & monthly updates for stock screens
  • A+ Investor Full access to AAII.com, Journal, and a power data suite for investment ideas
  • AAII Platinum Full access to all of AAII's model portfolios and premium services at a significant discount
  • Dividend Investing Newsletter and model portfolio that focuses on dividend growth
  • AAII Growth Investing Find secular growth stocks poised for outperformance regardless of macroeconomic conditions.
  • Retirement Investing Discover trusted strategies for every stage of retirement. Get actionable insights and resources for smart retirement planning.
  • Sentiment Investing A research-driven newsletter with 10+ signals decoding sentiment across retail and institutional behavior.
  • Stock Superstars Report Get stock ideas inspired by the market's leading professionals
  • VMQ Stocks For the value investor looking to harness academic research in an actively managed portfolio
  • Bits and Bips Newsletter delivering insights on linking traditional finance, macro trends and cryptocurrency opportunities to help investors build stronger, more diversified portfolios.
All premium products come with free basic membership.
Explore All Membership Options
Join Now

Stock Evaluator: uniQure N.V. (QURE)

uniQure N.V. QURE

$44.47 -1.53 -3.33%
September 10, 2026 4:00:00 PM EST November 10, 2021 Volume: 923,222
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Commentary & Analysis

Financial Summary

Share Statistics QURE Industry
Median		 Percentile
(All Stocks)
Market Cap (Mil) $3,084.7 $272.7 60%
Shares Out (Mil) 66.2 54.1 54%
Institutional Ownership 98.0% 93.0% 77%
Float (Mil) 57.5 42.3 50%
Beta 0.94 0.95 56%
Avg Daily Volume (000s) 1,243 471 75%
Price Change
(52-week)		 154.3% 56.7% 96%
Growth QURE Industry
Median		 Percentile
(All Stocks)
Sales (5yr) (15.6%) 14.1% 3%
Net Income (5yr) (9.7%) (10.1%) 29%
EPS (5yr) (4.2%) 15.7% 26
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) 14.5% (15.6%) 72%
Estimates Qtrly Current
Fiscal
Year		 Next
Fiscal
Year
# of Estimates 10 10 10
Current EPS ($0.955) ($3.983) ($3.054)
Month Ago EPS ($0.957) ($3.999) ($3.017)
# Rev Up 2 1 2
# Rev Down 0 0 1
Three Months Ago EPS ($0.874) ($3.478) ($2.833)
Year/Year Chg (22.0%) 15.1% (82.5%)
Financials QURE Industry
Median		 Percentile
(All Stocks)
Sales (TTM) (Mil) $19 $37 13%
Net Income (TTM) (Mil) ($252) ($43) 5%
EPS (TTM) ($4.036) ($1.600) 9%
Operating Cash Flow (TTM) (Mil) ($161) ($31) 4%
Net Cash Flow (TTM) (Mil) $159 $2 82%
Long-Term Debt (Q1) (Mil) $549 $4 60%
Enterprise Value (Q1) (Mil) $2,772 $185 53%
Valuation QURE Industry
Median		 Percentile
(All Stocks)
P/B 9.52 2.68 90%
P/E na 19.6 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.0 na
Ratios QURE Industry
Median		 Percentile
(All Stocks)
Gross Margin (614.3%) 67.6% 0%
Net Margin na (73.5%) na
ROA (32.1%) (47.9%) 16%
ROE (157.6%) (55.0%) 6%
Liabilities to Assets 67.1% 29.7% 63%
F-Score 4 3 33%

uniQure N.V. did not pass any screens on 9/10/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors